Evidence map›Paper›PMID 40199775›Full record

ArticleSleep & breathing = Schlaf & Atmung2025

The impact of PAP therapy first impression on short-term treatment adherence.

Monica Amendolara, Valentina Di Lecce, Carla Santomasi, Vitaliano Nicola Quaranta, Andrea Portacci, Ilaria Dei Lazzaretti, Laura Anna Sara Cuccaro, Massimo Casparrini, Sebastiano Spierto, Vito Picerno and 4 more

Abstract read
In one paragraph

Article in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Monica Amendolara *Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Valentina Di Lecce *Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Carla SantomasiInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Vitaliano Nicola QuarantaInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Andrea PortacciInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy. andrea.portacci@uniba.it.ORCID 0000-0002-6127-2486
Ilaria Dei LazzarettiInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Laura Anna Sara CuccaroInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Massimo CasparriniInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Sebastiano SpiertoInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Vito PicernoInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Cristina De RobertisInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Sara QuarantaInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Silvano DragonieriInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.
Giovanna Elisiana CarpagnanoInstitute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", 70124, Bari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePositive airway pressure (PAP) treatment for obstructive sleep apnea syndrome (OSAS) is often burdened by lower adherence rates. Patients' perception and acceptance of PAP therapy play a crucial role in achieving acceptable adherence.

methodWe conducted a prospective cohort study to assess patients' initial impressions of PAP therapy using a six-item questionnaire. The questionnaire evaluated CPAP tolerance, interface comfort, titration pressure, likelihood of CPAP use, expected health benefits, and overall attitude toward PAP therapy. Patients underwent a baseline awake PAP therapy trial (T0) followed by titration with an automatic device (APAP). After one month of titration, a fixed CPAP value was set (T1). Follow-ups occurred at 1 (T2), 3 (T3), and 6 (T4) months after the start of treatment. Adherence to PAP therapy was considered sufficient if the mean device usage was ≥ 4 h/night at T4.

resultsAfter six months, 77% of the enrolled patients achieved high PAP treatment adherence. Questionnaire scores generally improved from T0 to T4, particularly in CPAP tolerance, likelihood of treatment adherence, expected health benefits, and overall judgment of PAP therapy. Time-to-event analysis revealed that higher baseline scores in titration pressure comfort, likelihood of CPAP adherence, and overall judgment of PAP therapy were significantly associated with higher adherence likelihood.

conclusionPatients' first judgement on PAP therapy could significantly influence short-term adherence. Early identification and management of patients' complaints and discomforts could improve adherence rates and PAP perception over time.

Indexed as

Continuous Positive Airway PressurePatient ComplianceSleep Apnea, ObstructiveAdultAgedCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesSurveys and QuestionnairesAdherenceCPAPInterfacePressureQuestionnaireTolerance

Identifiers

PMID40199775
PMCPMC11978682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.